








key: cord-255174-h1izji2g
authors: Wei, Yuan-Yuan; Wang, Rui-Rui; Zhang, Da-Wei; Tu, You- Hui; Chen, Chang- Shan; Ji, Shuang; Li, Chun-Xi; Li, Xiu-Yong; Zhou, Meng-Xi; Cao, Wen- Sheng; Han, Ming- Feng; Fei, Guang-He
title: Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China
date: 2020-04-17
journal: J Infect
DOI: 10.1016/j.jinf.2020.04.010
sha: 
doc_id: 255174
cord_uid: h1izji2g

nan

dysfunction (1, (3) (4) (5) . Due to a previous lack of in-depth research on the characteristics of the disease, the mortality of severe illness is high(4). It is very important to analyse the clinical characteristics of COVID-19 in international regions and identify risk factors to reduce the incidence of severe and critical illness in the early stage. In this letter, we present discrepancies of patients with different disease severities and risk factors for severe COVID-19 by comparing and analysing epidemiological and clinical data of 167 confirmed patients in Anhui, China.

In the present study, the rate of severely ill patients was as high as 17.9%. Comparisons of demographics and clinical characteristics between 30 severe and 137 non-severe patients are shown in table 1. The mean age was 49.03 years in severe patients and 40.83 years in non-severe patients, with a significant difference (p=0.007). There were 95 males (56.89%) and 72 females (43.11%); however, there was no significant differences in sex between the two groups. Among 167 patients, 146 had fever (87.43%), 132 had cough (79.04%) and 61 had shortness of breath (36.53%). The prevalence of shortness of breath was 73.33% in severe patients, which was significantly greater than the 28.47% prevalence in non-severe patients (p<0.001). There were 44 patients (26.35%) with comorbidities, of which 9 had multiple comorbidities (5.39%). Among patients with diabetes, severe cases were significantly more common than in non-severe patients (p<0.001). Compared to non-severe patients, fingertip oxygen saturation decreased significantly in severe patients (p<0.001), which predisposed patients with chronic obstructive pulmonary disease to acute exacerbation. Since SARS-CoV-2 affected multiple organs by binding angiotensin converting enzyme 2 (ACE2) receptor(6) and many severe COVID-19 patients had comorbidities, multidisciplinary team (MDT) consultation played an important role in reducing the mortality of severe infection. There were significant differences in the use of mechanical ventilation, glucocorticoids and immunoglobulin between severe and non-severe patients (all p<0.05). Table 2 presents comparisons of laboratory parameters between severe and non-severe patients.

Lymphocyte, CD4 and CD8 cell counts were decreased significantly in severe patients compared to non-severe patients (p=0.004, 0.021 and 0.002), suggesting that T lymphocytes were seriously destroyed.

The increased level of c-reactive protein (CRP) in severe patients was significantly higher than that in non-severe patients (p=0.001). Interleukin-6 (IL-6) levels increased in 122 patients (73.05%); the increase was more significant in severe patients than in non-severe (p=0.001). By clearing or blocking inflammatory factors(7), artificial liver therapy and tocilizumab, a monoclonal antibody of IL-6 receptor, may prevent serious injuries in the lungs in severe patients. The lactate dehydrogenase (LDH) concentration was higher and the albumin concentration was lower in severe patients, with significant differences (p=0.002 and p<0.001). In severe patients, the fibrinogen concentration was significantly higher (p=0.008) than in non-severe patients, suggesting that severe patients were more likely to experience myocardial infarction or sudden death. Between the two groups, there was a significant difference in the neutrophil to lymphocyte ratio (NLR), a predictor for severe infection(8) (p=0.033).

Other laboratory parameters that changed in COVID-19 patients were not significantly different between the two groups (all p>0.05). There are still no specific therapies for COVID-19(1); nevertheless, assessing risk factors and symptomatic treatment in the early stage of the disease can improve the prognosis. Of 167 patients, 99.40% received initial antiviral therapy using lopinavir and ritonavir (400 mg/100 mg, bid) for no more than 10 days and/or atomized inhalation of interferon-α except for a 2-year-old patient, who was given interferon-α only, and 25.15% of patients received 40 mg methylprednisolone for 3 to 5 days. A total of 16.17% of patients were supported with immunoglobulins, and 13.18% of patients were managed with suitable oxygen therapy. All severe patients received MDT consultation, and three critical patients were treated with artificial liver therapy every other day, three times consecutively. Finally, all patients in our study, both severe or non-severe, improved and were discharged without death.

The clinical characteristics of 167 COVID-19 patients are summarized in tables 1 and 2. The similarities and differences between severe and non-severe patients in this letter suggested that elderly patients with multiple comorbidities, hypoxia, decreased CD4 and CD8 cell counts and increased levels of CRP and IL-6 are all closely associated with disease severity and prognosis, which should be assessed seriously during diagnosis and treatment. A rapid decline in T lymphocytes and significant increases in the levels of inflammatory factors, including CRP and IL-6, can be clinical warnings of severe infection.

MDT consultation and artificial liver therapy are very effective methods for severe patients with COVID-19. With these integrated prevention and treatment strategies, there will be a good prognosis for COVID-19. A. Mono-factor logistic regression analysis was used to analyse risk factors for severe illness using R software; B. Multi-factor logistic regression analysis was used to analyse independent risk factors for severe illness using R software.

Notes: P<0.05 indicates a risk factor in figure 1A and an independent risk factor in figure 1B for severe patients. 

Coronavirus 2019-nCoV: A brief perspective from the front line

We thank the medical workers fighting against COVID-19 for their hard work and sincere responses to our information requests.

Funding. This work was funded by the Key Technology Research and Development Program of Anhui Province (No: 1804h08020237).

